CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2018 ASPHO Conference
Oncology Conference Multimedia
View more videos >>
Dr. Engel on the Use of Eltrombopag in HIV-Related Thrombocytopenia
Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors
Dr. Bailey Discusses Key Molecular Pathways in Bone Sarcoma
Oncology Conference Articles
Expert Explains State of TKI Treatment in Pediatric CML
Discontinuation of tyrosine kinase inhibitor treatment may be a possibility for children with chronic myeloid leukemia and, because they could be on-treatment for decades, treatment-free remission is even more important for pediatric patients than for adults.
Eltrombopag Improves Platelet Count in Pediatric HIV
Eltrombopag (Promacta) boosted the platelet count in a 13-year-old boy with HIV-associated thrombocytopenia, according to case study results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.
COG to Assess Targeted Therapies in a Variety of NHL Clinical Trials
The Children's Oncology Group is currently involved in 5 studies exploring targeted therapies in non-Hodgkin lymphoma (NHL) that could eventually change the face of pediatric NHL treatment.
Tisagenlecleucel Safety, Efficacy Promising in Pediatric Down Syndrome and ALL
A first-time study of chimeric antigen receptor T-cell therapy in youths with Down syndrome-associated relapsed/refractory (r/r) acute lymphoblastic leukemia produced high remission rates and toxicity results that were similar to those observed in patients with r/r ALL.
Tazemetostat Shows Antitumor Activity in INI1-Negative Pediatric Tumors
Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors.
Selective T-Cell Depletion Improves Engraftment, Reduces GVHD in Pediatric/AYA Leukemia
Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.
2B8T2M Enhances exPBNK Expression, in Vitro Cytotoxicity in Rituximab-Sensitive/Resistant Burkitt Lymphoma
2B8T2M, a fusion of the IL-15 superantagonist ALT-803, and 4 single-chains of rituximab (Rituxan) significantly boosted the cytotoxicity of expanded peripheral blood natural killer cells against Burkitt lymphoma cells in in vitro testing.
CAR T-Cell Therapy May Serve as a Bridge to HCT in ALL
CAR T-cell therapy can induce next generation sequencing negativity in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting a "synergistic" relationship with hematopoietic cell transplant.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Durvalumab Improves Survival in Stage III NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.